Kyoto Prefectural University of Medicine / 京都府立医科大学

Drug- and Cell-Type-Specific Effects of ROCK Inhibitors as a Potential Cause of Reticular Corneal Epithelial Edema (2025) Schlötzer-Schrehardt U, Gießl A, Zenkel M, Bartsch A, Okumura N, Koizumi N, Kinoshita S, et al. Journal article Sex-Dependent Variations in Gene Expression in Corneal Endothelial Cells among Healthy Individuals and Patients with Fuchs Endothelial Corneal Dystrophy (2025) Nakagawa T, Tateishi A, Tokuda Y, Nakano M, Tashiro K, Tourtas T, Schlötzer-Schrehardt U, et al. Journal article Dysregulation of the TCF4 Isoform in Corneal Endothelial Cells of Patients With Fuchs Endothelial Corneal Dystrophy (2024) Honda T, Nakagawa T, Yuasa T, Tokuda Y, Nakano M, Tashiro K, Tourtas T, et al. Journal article RNA-Seq–based transcriptome analysis of corneal endothelial cells derived from patients with Fuchs endothelial corneal dystrophy (2023) Nakagawa T, Tokuda Y, Nakano M, Komori Y, Hanada N, Tourtas T, Schlötzer-Schrehardt U, et al. Journal article Novel NCOA2/3-rearranged low-grade fibroblastic spindle cell tumors: A report of five cases (2023) Bakhshwin A, Armstrong SM, Duckworth LA, Stöhr R, Konishi E, Rubin BP, Fritchie KJ, et al. Journal article RNA-Seq based transcriptome analysis of corneal endothelial cells derived from the patients with Fuchs endothelial corneal dystrophy (2022) Nakagawa T, Okumura N, Komori Y, Hanada N, Tokuda Y, Nakano M, Tourtas T, et al. Conference contribution A Close Look at the Clinical Efficacy of Rho-Associated Protein Kinase Inhibitor Eye Drops for Fuchs Endothelial Corneal Dystrophy (2021) Kinoshita S, Colby KA, Kruse F Journal article Potential Functional Restoration of Corneal Endothelial Cells in Fuchs Endothelial Corneal Dystrophy by ROCK Inhibitor (Ripasudil) (2021) Schlötzer-Schrehardt U, Zenkel M, Strunz M, Gießl A, Schondorf H, da Silva H, Schmidt GA, et al. Journal article Defining dry eye from a clinical perspective (2020) Tsubota K, Pflugfelder SC, Liu Z, Baudouin C, Kim HM, Messmer EM, Kruse F, et al. Journal article, Review article Elotuzumab, lenalidomide, and dexamethasone in RRMM: final overall survival results from the phase 3 randomized ELOQUENT-2 study (2020) Dimopoulos MA, Lonial S, White D, Moreau P, Weisel K, San-Miguel J, Shpilberg O, et al. Journal article